• CD109, STAT3, and Chemoresistance in Colorectal Cancer

  2026-09-03

  A 2026 study identifies CD109 as a regulator of colorectal cancer stemness and chemoresistance through an LRRC8A/AKAP12/PKCα signaling complex that activates STAT3 and WNT pathways. Its combination of patient-data analysis, mechanistic cell studies, pharmacological and genetic perturbation, and metastasis models provides a framework for studying CD109 as a therapeutic vulnerability in advanced disease.

• Ibuprofen as an Emerging Contaminant: Key Evidence

  2026-09-03

  Jan-Roblero and Cruz-Maya’s review reframes ibuprofen as both a widely used COX inhibitor and a persistent emerging contaminant with documented toxicological effects in aquatic systems. Its main practical contribution is the integration of environmental occurrence, biological damage, and bacterial biodegradation research, while highlighting the limitations of current removal strategies.

• EGTA: From Calcium Control to Translational Insight

  2026-09-02

  EGTA, or egtazic acid, is more than a calcium-binding reagent: it is a mechanistic probe for separating calcium-dependent signaling from channel-specific pharmacology. By connecting the anchor study of agatoxin-sensitive calcium channels in cardiac vagal neurons with neuroprotection and translational assay design, this article outlines how researchers can use EGTA rigorously without overinterpreting chelation data.

• HyperFluor 488 Goat Anti-Mouse IgG in Vascular Assays

  2026-09-02

  Discover how HyperFluor 488 Goat Anti-Mouse IgG supports spatial, cellular, and protein-level analysis of radiation-induced endothelial injury. This guide connects secondary-antibody design with the resveratrol rescue model while emphasizing controls, quantitative interpretation, and assay selection.

• CIH, Gut Metabolites, and Mitochondrial Apoptosis

  2026-09-01

  The reference study connects chronic intermittent hypoxia with lung apoptosis through coordinated changes in gut microbiota, fatty-acid metabolism, and mitochondrial injury. By combining 16S rRNA sequencing, GC–MS metabolomics, tissue pathology, and pharmacological perturbation with Mdivi-1 and CCCP, it proposes a gut microbiota–metabolite–mitochondrial axis that may help explain obstructive sleep apnea-related tissue damage.

• EdU Flow Cytometry Assay Kits (Cy3) Guide

  2026-09-01

  EdU Flow Cytometry Assay Kits (Cy3) detect DNA synthesis through selective click chemistry without the DNA denaturation required by many BrdU workflows. The K1077 format supports quantitative cell cycle analysis by flow cytometry and can be adapted to proliferation, genotoxicity, and pharmacodynamic studies.

• Lumiracoxib Workflows for COX-2 Research

  2026-08-31

  Build cleaner COX-2 pathway experiments with Lumiracoxib, from biochemical inhibition assays to time-resolved inflammation and revascularization models. Its high COX-1 selectivity helps separate prostaglandin synthesis inhibition from broader cyclooxygenase effects, while a staged workflow exposes when COX-2 activity is protective or maladaptive.

• HotStart™ 2X Green qPCR Master Mix Guide

  2026-08-31

  HotStart™ 2X Green qPCR Master Mix is intended for SYBR Green real-time PCR of cDNA or DNA when nonspecific amplification and primer-dimer formation could compromise quantification. It is suitable for gene expression analysis, RNA-seq validation, and nucleic acid quantification after assay validation, but it should not be used as a direct RNA amplification reagent or treated as a probe-specific chemistry without separate validation.

• Phosbind Acrylamide: 5 Lab Scenarios

  2026-08-30

  This scenario-based guide explains how Phos binding reagent (Phosbind) acrylamide, SKU F4002, can support antibody-free SDS-PAGE phosphorylation analysis alongside cell viability, proliferation, and cytotoxicity studies. It covers compatibility, gel preparation, storage, mobility-shift interpretation, and practical vendor selection using product specifications and published phosphorylation research.

• Ferrostatin-1 (Fer-1) in Ferroptosis Assays

  2026-08-29

  Ferrostatin-1 (Fer-1) provides a practical rescue control for distinguishing lipid peroxidation–driven death from nonspecific cytotoxicity. This workflow applies Fer-1 to colorectal cancer studies, HDAC3–NRF2–GPX4 pathway analysis, and carefully bounded extensions into neuronal models.

• BCL-XL inhibitor A-1155463: Applied Research Workflow

  2026-08-28

  Build sharper apoptosis studies with a high-affinity, selective BCL-XL inhibitor that helps distinguish BCL-XL dependence from nonspecific cytotoxicity. This workflow covers model selection, dose-response design, mechanistic validation, resistance studies, and translational interpretation.

• HotStart™ 2X Green qPCR Master Mix for dAGE Studies

  2026-08-28

  Discover how HotStart™ 2X Green qPCR Master Mix can translate dAGE–myriocin biology into a defensible gene-expression assay strategy. This article connects SYBR Green chemistry, mechanism-resolving marker selection, and interpretation limits for metabolic research.

• Forsythoside E for PKM2 Macrophage Assays

  2026-08-27

  Forsythoside E connects PKM2 tetramerization with macrophage metabolic remodeling, making it useful for mechanism-driven inflammation and sepsis-induced liver injury research. This workflow pairs glycolysis, signaling, polarization, and target-engagement readouts instead of relying on cytokine measurements alone.

• FH1 and the Next Control Layer in Liver Research

  2026-08-27

  FH1 links iPS-derived hepatocyte maturation with a broader translational strategy: build more functional liver cell models first, then evaluate regulated gene expression in a biologically relevant context. This perspective connects FH1 (Catalog No. B3700) with the light-inducible RNA-releasing protein platform described in Trends in Biotechnology while clearly separating established findings from forward-looking research opportunities.

• IGFBP2–THBS1 Axis in GH-Mediated Bone Growth

  2026-08-26

  A 2025 study identifies an IGFBP2–THBS1 regulatory axis that helps explain how growth hormone promotes chondrocyte proliferation and hypertrophic differentiation in idiopathic short stature. Its combination of ISS-associated plasma proteomics, interaction prediction, and functional gene perturbation links GH exposure to IGF-1 pathway activity and suggests a mechanistic framework for studying variable treatment responses.

8394 records 1/560 page Next 12345 下5页 Last page